溴尿嘧啶
可药性
表观遗传学
蛋白质水解
生物
小分子
细胞生物学
蛋白质降解
BRD4
药物发现
生物化学
酶
化学
基因
作者
Thang Do Cong,Jun Wei Lau,Caixia Sun,Songhan Liu,Tuan-Khoa Kha,Seok Ting Lim,Yu Yang Oon,Yuet Ping Kwan,Jiajia Ma,Yuguang Mu,Xiaogang Liu,Thomas James Carney,Xiaomeng Wang,Bengang Xing
出处
期刊:Science Advances
[American Association for the Advancement of Science (AAAS)]
日期:2022-12-14
卷期号:8 (50)
被引量:27
标识
DOI:10.1126/sciadv.abq2216
摘要
Epigenetic mediation through bromodomain and extraterminal (BET) proteins have progressively translated protein imbalance into effective cancer treatment. Perturbation of druggable BET proteins through proteolysis-targeting chimeras (PROTACs) has recently contributed to the discovery of effective therapeutics. Unfortunately, precise and microenvironment-activatable BET protein degradation content with promising tumor selectivity and pharmacological suitability remains elusive. Here, we present an enzyme-derived clicking PROTACs (ENCTACs) capable of orthogonally cross-linking two disparate small-molecule warhead ligands that recognize BET bromodomain-containing protein 4 (BRD4) protein and E3 ligase within tumors only upon hypoxia-induced activation of nitroreductase enzyme. This localized formation of heterobifunctional degraders promotes specific down-regulation of BRD4, which subsequently alters expression of epigenetic targets and, therefore, allows precise modulation of hypoxic signaling in live cells, zebrafish, and living mice with solid tumors. Our activation-feedback system demonstrates compelling superiorities and may enable the PROTAC technology with more flexible practicality and druggable potency for precision medicine in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI